Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 1:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 9,926 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single-arm Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Photodynamic Therapy for Papulopustular Rosacea

NCT02075671
View directory record Official record
Conditions
Rosacea, Papulopustular Rosacea
Interventions
Aminolevulinic acid topical solution 20%, Blu-U Light Therapy, Placebo vehicle only
Drug · Device · Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Nov 1, 2026, 1:06 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Naproxen Pharmacogenetic Study (Project 1, Aim 2)

NCT04449471
View directory record Official record
Conditions
Pharmacogenetics
Interventions
Naproxen tablet
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Nov 1, 2026, 1:06 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

NCT03569371
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
INCB054707
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Nov 1, 2026, 1:06 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Drospirenone-only Pill as Emergency Contraception

NCT05675644
View directory record Official record
Conditions
Contraception
Interventions
Drospirenone-only pill
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Nov 1, 2026, 1:06 AM EDT
Terminated Phase 4 Interventional Results available

Efficacy Of Combined Nebulized Hypertonic Saline and Chest Percussion Therapy in Acute Viral Bronchiolitis

NCT06441162
View directory record Official record
Conditions
Acute Bronchiolitis
Interventions
Nebulized 3% sodium chloride solution, Chest percussion cups
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
0 Months to 24 Months
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Nov 1, 2026, 1:06 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

NCT04989946
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, pTVG-AR, Nivolumab, Cemiplimab, Fianlimab, FLT PET/CT
Drug · Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Nov 1, 2026, 1:06 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Transmitted Lung Pressures With Biphasic Chest Cuirass

NCT03799588
View directory record Official record
Conditions
Lung Diseases
Interventions
Biphasic Chest Cuirass
Device
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
6 Months to 5 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Nov 1, 2026, 1:06 AM EDT
Terminated Phase 2 Interventional Results available

BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A

NCT00623727
View directory record Official record
Conditions
Hemophilia A
Interventions
rFVIII-FS/pegylated liposomes (BAY79-4980), rFVIII-FS/WFI (BAY14-2222)
Biological
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 70 Years · Male only
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
20
States / cities
Orange, California • Sacramento, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Nov 1, 2026, 1:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

NCT06040970
View directory record Official record
Conditions
Ovarian Cancer, Malignant Neoplasm of Uterus
Interventions
Sacituzumab, Cisplatin
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 1, 2026, 1:06 AM EDT
Completed Phase 2 Interventional

Immune Effects of Vitamin D in Hemodialysis Patients

NCT00686751
View directory record Official record
Conditions
End Stage Renal Disease, Hemodialysis, Inflammatory Response, Cardiovascular Disease
Interventions
paricalcitol
Drug
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2009 · Synced Nov 1, 2026, 1:06 AM EDT
Completed Phase 2 Interventional Results available

Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma

NCT01239394
View directory record Official record
Conditions
Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
Interventions
ofatumumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Nov 1, 2026, 1:06 AM EDT
Completed Not applicable Interventional Results available

Same-session MR-only Simulation and Treatment With MRI-guided Adaptive Palliative RadioTherapy

NCT03824366
View directory record Official record
Conditions
Malignancy, Metastasis, Hemoptysis, Gastrointestinal Bleeding, Pelvic Bleeding, Superior Vena Cava Syndrome, Mediastinal Disease
Interventions
Volumetric MR imaging, Radiation therapy
Device · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Nov 1, 2026, 1:06 AM EDT
Completed Phase 2 Interventional

Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower Extremities

NCT00493051
View directory record Official record
Conditions
Diabetic Foot
Interventions
GAM501, Placebo, Standard of care
Biological · Other
Lead sponsor
Tissue Repair Company
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
29
States / cities
Montgomery, Alabama • Mesa, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Nov 1, 2026, 1:06 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Mobile Intervention for Young Opioid Users

NCT03610672
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
OD prevention/response training, OD prevention/response training + PI mobile application
Behavioral
Lead sponsor
National Development and Research Institutes, Inc.
Other
Eligibility
18 Years to 29 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Nov 1, 2026, 1:06 AM EDT
Completed Not applicable Interventional Results available

Theta Burst Stimulation for Alcohol Use Disorder

NCT06060496
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Active cTBS, Sham cTBS
Device
Lead sponsor
Gopalkumar Rakesh
Other
Eligibility
21 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Nov 1, 2026, 1:06 AM EDT
Not listed Not applicable Interventional

Inspire® Post-Approval Study / Protocol Number 2014-001

NCT02413970
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Inspire® UAS System
Device
Lead sponsor
Inspire Medical Systems, Inc.
Industry
Eligibility
22 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Nov 1, 2026, 1:06 AM EDT
Completed Phase 2 Interventional Results available

Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

NCT01698905
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Beech Grove, Indiana • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Nov 1, 2026, 1:06 AM EDT
Active, not recruiting Phase 2 Interventional

Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation

NCT06990529
View directory record Official record
Conditions
PIDs Linked to PI3K
Interventions
Leniolisib
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
12 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Bethesda, Maryland • Burlington, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Nov 1, 2026, 1:06 AM EDT
Terminated Phase 1 Interventional

FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas

NCT02371031
View directory record Official record
Conditions
Glioma, Malignant Glioma
Interventions
6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine, PET/MRI, Surgical resection (standard of care)
Drug · Device · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Nov 1, 2026, 1:06 AM EDT
Completed Phase 2 Interventional Results available

Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT01767675
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tubes Cancer, Peritoneal Cancer
Interventions
Secondary Cytoreductive Surgery, Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC), platinum-based systemic chemotherapy postoperatively
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
11
States / cities
Hartford, Connecticut • Miami, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 1, 2026, 1:06 AM EDT
Completed Not applicable Interventional Results available

Congenital Heart Disease Physical Activity Lifestyle Study

NCT03335475
View directory record Official record
Conditions
Cardiovascular Disease Other, Physical Activity
Interventions
Physical Activity Lifestyle Intervention, Physical Activity Monitoring
Behavioral
Lead sponsor
Jamie Jackson
Other
Eligibility
15 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Nov 1, 2026, 1:06 AM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

NCT00884546
View directory record Official record
Conditions
Advanced Cancer, Various, NOS
Interventions
BMS-833923, Lenalidomide, Dexamethasone, Bortezomib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Nov 1, 2026, 1:06 AM EDT
Terminated Phase 2 Interventional Results available

Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

NCT04541173
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Y-90 TARE, Atezolizumab, Bevacizumab
Other · Drug
Lead sponsor
Aiwu Ruth He, MD
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Nov 1, 2026, 1:06 AM EDT
Completed Not applicable Interventional Results available

Outcomes in Rotator Cuff Repair Using Graft Reinforcement

NCT01025037
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
Conexa Reconstructive Tissue Matrix
Device
Lead sponsor
Stryker Trauma and Extremities
Industry
Eligibility
40 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
6
States / cities
Phoenix, Arizona • Chicago, Illinois • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Nov 1, 2026, 1:06 AM EDT